Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth
- PMID: 21325052
- PMCID: PMC3054028
- DOI: 10.1073/pnas.1014769108
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth
Abstract
Although aerobic glycolysis (the Warburg effect) is a hallmark of cancer, key questions, including when, how, and why cancer cells become highly glycolytic, remain less clear. For a largely unknown regulatory mechanism, a rate-limiting glycolytic enzyme pyruvate kinase M2 (PKM2) isoform is exclusively expressed in embryonic, proliferating, and tumor cells, and plays an essential role in tumor metabolism and growth. Because the receptor tyrosine kinase/PI3K/AKT/mammalian target of rapamycin (RTK/PI3K/AKT/mTOR) signaling cascade is a frequently altered pathway in cancer, we explored its potential role in cancer metabolism. We identified mTOR as a central activator of the Warburg effect by inducing PKM2 and other glycolytic enzymes under normoxic conditions. PKM2 level was augmented in mouse kidney tumors due to deficiency of tuberous sclerosis complex 2 and consequent mTOR activation, and was reduced in human cancer cells by mTOR suppression. mTOR up-regulation of PKM2 expression was through hypoxia-inducible factor 1α (HIF1α)-mediated transcription activation, and c-Myc-heterogeneous nuclear ribonucleoproteins (hnRNPs)-dependent regulation of PKM2 gene splicing. Disruption of PKM2 suppressed oncogenic mTOR-mediated tumorigenesis. Unlike normal cells, mTOR hyperactive cells were more sensitive to inhibition of mTOR or glycolysis. Dual suppression of mTOR and glycolysis synergistically blunted the proliferation and tumor development of mTOR hyperactive cells. Even though aerobic glycolysis is not required for breach of senescence for immortalization and transformation, the frequently deregulated mTOR signaling during multistep oncogenic processes could contribute to the development of the Warburg effect in many cancers. Components of the mTOR/HIF1α/Myc-hnRNPs/PKM2 glycolysis signaling network could be targeted for the treatment of cancer caused by an aberrant RTK/PI3K/AKT/mTOR signaling pathway.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Fig. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3054028/bin/pnas.1014769108fig01.gif)
![Fig. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3054028/bin/pnas.1014769108fig02.gif)
![Fig. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3054028/bin/pnas.1014769108fig03.gif)
![Fig. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3054028/bin/pnas.1014769108fig04.gif)
![Fig. 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3054028/bin/pnas.1014769108fig05.gif)
![Fig. 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3054028/bin/pnas.1014769108fig06.gif)
Similar articles
-
The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.Technol Cancer Res Treat. 2018 Jan 1;17:1533033818780063. doi: 10.1177/1533033818780063. Technol Cancer Res Treat. 2018. PMID: 29916308 Free PMC article.
-
PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade.J Biol Chem. 2014 Oct 24;289(43):29739-49. doi: 10.1074/jbc.M114.584821. Epub 2014 Aug 27. J Biol Chem. 2014. PMID: 25164809 Free PMC article.
-
Pyruvate kinase M2 and cancer: an updated assessment.FEBS Lett. 2014 Aug 19;588(16):2685-92. doi: 10.1016/j.febslet.2014.04.011. Epub 2014 Apr 18. FEBS Lett. 2014. PMID: 24747424 Review.
-
Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2.Mol Cancer. 2013 Jul 9;12:72. doi: 10.1186/1476-4598-12-72. Mol Cancer. 2013. PMID: 23837608 Free PMC article.
-
Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.Int J Biochem Cell Biol. 2011 Jul;43(7):969-80. doi: 10.1016/j.biocel.2010.02.005. Epub 2010 Feb 13. Int J Biochem Cell Biol. 2011. PMID: 20156581 Review.
Cited by
-
PKM2 functions as a histidine kinase to phosphorylate PGAM1 and increase glycolysis shunts in cancer.EMBO J. 2024 Jun;43(12):2368-2396. doi: 10.1038/s44318-024-00110-8. Epub 2024 May 15. EMBO J. 2024. PMID: 38750259 Free PMC article.
-
Urinary PKM2, a marker predicating acute kidney injury in patients with sepsis.Int Urol Nephrol. 2024 Apr 18. doi: 10.1007/s11255-024-04054-0. Online ahead of print. Int Urol Nephrol. 2024. PMID: 38635124
-
Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy.Acta Pharmacol Sin. 2024 Apr 15. doi: 10.1038/s41401-024-01264-1. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 38622288 Review.
-
Sex differences in colonic gene expression and fecal microbiota composition in a mouse model of obesity-associated colorectal cancer.Sci Rep. 2024 Feb 13;14(1):3576. doi: 10.1038/s41598-024-53861-z. Sci Rep. 2024. PMID: 38347027 Free PMC article.
-
AMPK Alchemy: Therapeutic Potentials in Allergy, Aging, and Cancer.Biomol Ther (Seoul). 2024 Mar 1;32(2):171-182. doi: 10.4062/biomolther.2023.222. Epub 2024 Feb 13. Biomol Ther (Seoul). 2024. PMID: 38346909 Free PMC article. Review.
References
-
- Pan JG, Mak TW. Metabolic targeting as an anticancer strategy: Dawn of a new era? Sci STKE. 2007;2007:pe14. - PubMed
-
- Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703–707. - PubMed
-
- Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. - PubMed
-
- Yoo YG, Hayashi M, Christensen J, Huang LE. An essential role of the HIF-1alpha-c-Myc axis in malignant progression. Ann N Y Acad Sci. 2009;1177:198–204. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous